top of page
Misty Slope

Our Research and Development

Changing the Game

Developing drugs for Alzheimer's disease has been extremely difficult. Firstly, the exact cause of Alzheimer's disease is still not fully understood. It is believed to be caused by a complex interplay of genetic, environmental, and lifestyle factors, making it difficult to identify specific drug targets. Secondly, the brain is a highly complex and intricate organ, which makes it difficult to develop drugs that can penetrate the blood-brain barrier and reach the affected areas of the brain. Thirdly, Alzheimer's disease is a progressive and degenerative condition, meaning that by the time symptoms appear, significant damage has already been done to the brain. This makes it difficult to develop drugs that can halt or reverse the disease's progression. Fourthly, clinical trials for Alzheimer's drugs have had a very high failure rate, with many promising candidates failing to demonstrate efficacy in large-scale studies. This may be due to the heterogeneity of the disease and the difficulty in identifying appropriate patient populations. Finally, Alzheimer's disease is a complex and multifaceted condition, with a range of symptoms that can vary widely between individuals. This makes it difficult to develop drugs that can effectively target all aspects of the disease.

LA PharmaTech, to the forefront of a new drug development strategy, is developing innovative drug combinations to attack the complex causes of Alzheimer's disease through multiple mechanisms of actions. 

LA PharmaTech is working with The Jackson Laboratory and Charles River Laboratories to test our innovative drug combination with different Alzheimer's disease animal models. 

Our founder, Jim Wang, has over 20 years of drug research and development experience in both big pharma settings, such as DuPont Pharmaceuticals and Bristol-Myers Squibb and small pharma tech settings such as Athersys and New River Pharma. With his leadership, we are navigating through the Amazon Rainforest-like potential solutions for Alzheimer's disease and believe we will climb to the top of the mountain of seeking the treatment solutions for AD within a few years.

About: About Us
bottom of page